Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Update

Dermata Therapeutics, Inc. (NASDAQ:DRMA) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 142,900 shares, an increase of 11.3% from the December 15th total of 128,400 shares. Based on an average daily trading volume, of 310,400 shares, the short-interest ratio is currently 0.5 days. Currently, 7.1% of the shares of the company are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Dermata Therapeutics stock. Armistice Capital LLC bought a new position in shares of Dermata Therapeutics, Inc. (NASDAQ:DRMA) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 28,000 shares of the company’s stock, valued at approximately $67,000. Armistice Capital LLC owned about 4.98% of Dermata Therapeutics at the end of the most recent reporting period. Institutional investors own 8.67% of the company’s stock.

Dermata Therapeutics Stock Performance

Shares of NASDAQ DRMA remained flat at $1.33 during mid-day trading on Friday. The company had a trading volume of 65,599 shares, compared to its average volume of 244,543. The stock has a market cap of $2.71 million, a price-to-earnings ratio of -0.08 and a beta of 0.66. The stock’s fifty day moving average price is $1.24 and its 200 day moving average price is $1.60. Dermata Therapeutics has a 52-week low of $1.00 and a 52-week high of $8.66.

About Dermata Therapeutics

Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.